Green Griffith successfully defended one of Horizon’s Orange Book-listed patents (U.S. 8,642,012) for its RAVICTI® oral liquid product at the Federal Circuit against Par Pharmaceutical’s appeal of an unsuccessful inter partes review (“IPR”) proceeding. In a decisive win, the Federal Circuit affirmed per curiam (without opinion) the Patent Trial and Appeal Board’s (“PTAB”) decision upholding the patentability of Horizon’s ’012 patent.
